Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952

Köhne, C.-H.; Wils, J.; Lorenz, M; Schöffski, Patrick; Voigtmann, R.; Bokemeyer, Carsten; Lutz, Manfred P.; Kleeberg, Ulrich R.; Ridwelski, K.; Souchon, R.; El-Serafi, M.; Weiss, Ulrich F; Burkhard, Oswald; Rückle, H.; Lichinitser, Mikhail; Langenbuch, T.; Scheithauer, Werner; Baron, B.; Couvreur, M.L.; Schmoll, H.-J.

doi:10.1200/jco.2003.11.122

Cited by 149 publications

(70 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A phase II study of high-dose 5-FU (2600 mg m À2 ) and FA (500 mg m À2 ), German AIO regimen, has also been reported as a salvage regimen in gastric cancer with partial remissions of 18% and stable disease of 41% (Vanhoefer et al, 1994). The decreased dose of FA (300 mg m À2 ) in our HDFL compared to German AIO regimen may also decrease the toxicity of grade 3/4 diarrhoea (Kohne et al, 2003). Further, results of our in vitro studies have implied that strict avoidance of bolus injection of 5-FU is the key to avoid myelosuppression (Yeh et al, 2000a).…”

Section: Discussionmentioning

confidence: 77%

Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer

et al. 2004

View full text Add to dashboard Cite

To investigate the efficacy and safety of combining weekly oxaliplatin with weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and folinic acid (FA) in treatment of patients with advanced gastric cancer. Patients with histologically confirmed, locally advanced or recurrent/metastatic gastric cancer were studied. Oxaliplatin 65 mg m À2 2-h intravenous infusion, and 5-FU 2600 mg m À2 plus FA 300 mg m À2 24-h intravenous infusion, were given on days 1 and 8, repeated every 3 weeks. Between January 2001 through January 2002, 55 patients were enrolled. The median age was 64 years (range: 22 -75). In all, 52 patients (94.5%) had recurrent or metastatic disease and three patients had locally advanced disease. Among 50 patients evaluable for tumour response, 28 patients achieved partial response, with an overall response rate of 56% (95% confidence interval (CI): 41.8 -70.3%). All 55 patients were evaluated for survival and toxicities. Median time to progression and overall survival were 5.2 and 10.0 months, respectively, during median followup time of 24.0 months. Major grades 3 -4 toxicities were neutropenia in 23 cycles (7.1%) and thrombocytopenia in 16 cycles (5.0%). Treatment was discontinued for treatment-related toxicities in nine patients (16.4%), of whom eight were due to oxaliplatin-related neurotoxicity. One patient (1.8%) died of neutropenic sepsis. This oxaliplatin-containing regimen is effective in the treatment of advanced gastric cancer. Except for neurotoxicity that often develops after prolonged use of oxaliplatin, the regimen is well tolerated.

show abstract

Section: Discussionmentioning

confidence: 77%

Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer

et al. 2004

View full text Add to dashboard Cite

show abstract

“…Randomized trials have shown that infusional administration of FU/FA improves the tumor response rate (RR), increases time to tumor progression (TTP -in this review, we will make no distinction between TTP and progression-free survival) and marginally improves overall survival (OS) at reduced or similar toxicity (de Gramont et al, 1997;Ko¨hne et al, 2003), and the Mayo regimen should not be used anymore. In many parts of Europe, and increasingly in United States, modulated infusion regimens are preferred; the most commonly used approach is probably the 'de Gramont' regimen that combines FA, bolus FU and prolonged infusion FU (de Gramont et al, 1997;Ragnhammar et al, 2001;Meyerhardt and Mayer, 2005).…”

Section: Principles For Retrieval Of Datamentioning

confidence: 99%

Current role of antibody therapy in patients with metastatic colorectal cancer

2007

View full text Add to dashboard Cite

“…Four studies have compared investigational regimens against a Mayo Clinic (Rochester, MN) regimen control arm [13][14][15][16]. In each case, the median OS was not significantly different from control.…”

Section: Bolus or Infusion?mentioning

confidence: 99%

Therapy for Metastatic Colorectal Cancer

Goldberg

2006

The Oncologist

View full text Add to dashboard Cite

Learning ObjectivesAfter completing this course, the reader will be able to:1. Compare toxicity profiles among combination chemotherapy programs for colorectal cancer.2. Identify median survival times for chemotherapy programs for colorectal cancer. AbstractMedian overall survival of metastatic colorectal cancer patients treated with first-and second-line combination chemotherapy now extends to more than 20 months in some studies. Chemotherapy alone, particularly when oxaliplatin is included, may allow potentially curative resection of advanced disease. There is evidence that the addition of antibodies targeted against vascular endothelial growth factor or the epidermal growth factor receptor will further improve prospects for patients with advanced and metastatic disease. However, the optimum sequencing of chemo-and biological therapies remains to be established, as does the potential contribution of numerous agents in development. The Oncologist 2006;11:981-987

show abstract

Randomized Phase III Study of High-Dose Fluorouracil Given As a Weekly 24-Hour Infusion With or Without Leucovorin Versus Bolus Fluorouracil Plus Leucovorin in Advanced Colorectal Cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952

Abstract: Neither FU24h + LV nor FU24h prolong survival, relative to bolus FU + LV. Leucovorin increases PFS if added to FU24h, but increases toxicity.

Cited by 149 publications

References 17 publications

Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer

Phase II study of weekly oxaliplatin and 24-h infusion of high-dose 5-fluorouracil and folinic acid in the treatment of advanced gastric cancer

Current role of antibody therapy in patients with metastatic colorectal cancer

Therapy for Metastatic Colorectal Cancer

Contact Info

Product

Resources

About